Dr. Ron Paul's Warning to America

Editor's Note: Legendary 12-time U.S. Congressman Dr. Ron Paul has an urgent message for you. He's asked permission to write to you directly today. Please listen carefully to what he has to say... Dear Reader, I first went to Washington, D.C. 50 years ago. I served 12 terms. I ran for President three times. They called me "Dr. No." I've been called a "traitor" and a "crank." My own party even turned on me. But I've always stood up for what's right. I warned the Iraq war would be a disaster. I tried to warn Congress about the banks before 2008. And now, at the age of 91, I'm issuing a NEW warning to America. Put simply, a major crisis I spent 50 years trying to prevent is coming. It involves a dangerous experiment involving at least $27 billion... and 30 different U.S. companies, including several popular publicly listed stocks you may already own (get the names here). I tried to warn Congress myself. In fact, I dedicated much of my farewell to Congress speech to this dangerous new change. But what's happening in D.C. today has me as worried as at any other time in my life. I believe a new ideology that's every bit as dangerous as socialism is taking root amongst our political elite. And it could impact not just your money and retirement, but many of the stocks you already own. I can't stop Congress. And I can't stop the White House. But I CAN warn you directly... and show you exactly what you need to do with your money before it's too late. I explain everything you need to know 100% free of charge in this new interview. Regards, Dr. Ron Paul Former U.S. Congressman and Presidential Candidate P.S. I believe every American family needs to seriously consider taking three specific financial steps today. One of them could already have doubled your money several times. You can hear about all three of them, free of charge, by clicking right here. To ensure that you continue to receive marketing emails from TradeSmith, please add info@exct.tradesmith.com to your address book. If you no longer want to receive marketing emails from TradeSmith, please click here to unsubscribe. If you have any questions, please don't hesitate to contact Customer Service at support@tradesmith.com or by calling 1-866-385-2076. © 2026 TradeSmith, LLC. All Rights Reserved. 1125 N. Charles Street, Baltimore, MD 21201 Terms of Use  |  Privacy Policy  |  Unsubscribe

The Feedback Loop That Makes Options Move the Stock

From The Editor Larry’s Note: The Dollar Trap is tonight… I’ll be sitting down with Jeff Brown for an emergency briefing where we will break down why the U.S. dollar is in an inescapable trap that not even the president can stop from snapping shut. We’ll also reveal why the big AI winners could effectively lose up to 40% of their gains in the aftermath. The good news? You can turn this chaos into profits with the method we’ll share tonight. Just go here to automatically RSVP for tonight’s event. See you at 8 p.m. ET. The Feedback Loop That Makes Options Move the Stock Sometimes options don't just follow a stock – they move it. But the feedback loop that can send a stock soaring can reverse just as fast… Written by Larry Benedict Published on Sep 30, 2026 Most traders assume that options follow the price of the underlying stock. So if the stock price rises, its call options will typically increase in value. And if it falls, its put options will typically rise in value. That’s why options are known as “derivatives” – their value is derived from another asset. But sometimes that relationship can start working the other way around. When enough money starts flooding into short-dated options, the resulting activity can start to influence the underlying stock itself. Call option buying can help drive the stock higher, which in turn can attract more option buyers into the trade. It’s a feedback loop that can produce sharp moves in an extremely short period. But when that feedback loop breaks, the reversal can be just as sudden. That’s why traders need to understand what’s driving a move before deciding to jump on board.

Recommended Links Don’t Buy Bitcoin (Do This Instead) A former hedge fund manager whose firm Barron’s ranked in the top 1% worldwide says buying Bitcoin is the wrong move. His readers have had the chance to collect $4,898… $11,145… and even $17,350 from Bitcoin’s moves without owning a single coin. Now he’s revealing the whole strategy, free. Have Jeff Brown and Larry Benedict Lost Their Minds? Larry Benedict went 20 straight years on Wall Street without a losing year. Jeff Brown recommended Bitcoin at $240 and Nvidia in 2016. Now they’ve issued the biggest warning of their careers: The U.S. dollar will break on Wednesday, October 7, at 1:00 p.m. ET – on a deadline set by the federal government… It could lose up to a third of its value. Or even half… And the money doesn’t vanish. It moves into a market that could have potentially handed you over $410,000 the last time something like this happened. TONIGHT, September 30, at 8:00 p.m. ET, they share all the proof, free. Click here to reserve your seat for free. (When you click the link, your email address will automatically added to guest list)

How the Options Feedback Loop Works We’ve seen it a lot – especially throughout the AI boom. Suddenly, a stock becomes popular after releasing some positive news. But rather than buying the shares outright, many traders buy call options. That can become even more prevalent when stocks are trading in the high hundreds or even over $1,000. Calls enable traders to gain exposure to a stock for a fraction of what buying the shares would cost. That leverage can generate substantial percentage gains when the stock moves in the desired direction. However, someone must take the other side of every option trade. That role is often filled by a professional market maker. Market makers provide liquidity so that traders can buy and sell options when they wish. Those market makers don’t want to take a big directional bet on where the stock is going. Say they sell a large batch of call options. If those get exercised, they’re on the hook to hand over the stock. So to cut that risk, they may buy some of the underlying shares. If the stock keeps climbing, they may need to buy even more shares to keep their position hedged. And that’s where the feedback loop can take hold. Traders buy call options. Market makers buy shares to hedge some of that exposure. That helps drive the stock price higher, encouraging even more call option buyers to enter the market. It can become a case of the tail wagging the dog, so to speak. Before long, the options aren’t simply responding to the stock. Instead, option-related activity may also be helping propel the stock higher. To be clear, it doesn’t mean every surge in call option buying will produce the same result. Market makers may have other positions to offset that exposure. But when trading becomes heavily concentrated in the same short-dated options, hedging flows can really amplify a move. Tune in to Trading With Larry Live Each week, Market Wizard Larry Benedict goes live to share his thoughts on what’s impacting the markets. Whether you’re a novice or expert trader, you won’t want to miss Larry’s insights and analysis. Even better, it’s free to watch. Visit us on YouTube to catch the latest! Don’t Mistake Mechanical Demand for the Real Thing The problem comes when traders mistake that mechanically driven demand for a genuine improvement in the company’s prospects. They see the stock accelerating and assume that a new uptrend has begun. And these days, everyone’s connected – social media, trading sites, chat rooms. So the initial move can set off another wave of buying as traders fear missing out (FOMO). But eventually, that flow begins to dry up. Early traders start taking profits. New buyers become reluctant to pay inflated premiums. And with time decay accelerating as expiration approaches, those short-dated contracts can quickly lose much of their remaining value. When that happens, market makers may no longer need all the shares they bought as hedges. As they reduce those positions, that buying support can quickly disappear and even turn into net selling. Option buyers late to the move can see the value of their options collapse right in front of their eyes. That doesn’t mean these moves can’t be traded – far from it. Option-driven momentum can be very real – and potentially highly profitable to trade. But you don’t want to confuse a short-term feedback loop with genuine, sustainable investor demand. That’s why I watch for a few warning signs: heavy or unusual activity in short-dated options, premiums rising fast, or big volume piling up around certain strike prices. I’m also wary if a stock’s move appears completely out of proportion to the associated news. Options can create tremendous trading opportunities. But once option activity starts moving the stock, traders need to understand that any move could be short-lived — and fade as fast as it arrived. Happy Trading, Larry Benedict Editor, Trading With Larry Benedict Get Instant Trade Alerts on Mobile! Click the icon below from your mobile device to download The Opportunistic Trader app today for one-tap access to trade alerts, issues, and model portfolios for all of Larry’s services. Available in the app store on Android and iPhone. More stories like this Read the latest analysis on hot growth stocks, and market-moving developments The Q4 Trap: Don’t Let the Calendar Control Your Trading As the final quarter begins, the urge to chase a year-end comeback can wreck your account. Here’s why discipline beats the deadline… Sep 29, 2026 • 3 min read Why Beaten-Down Financials Are Primed for a Bounce Market breadth just hit an extreme not seen since March. Here's why beaten-down financials like XLF could be primed for a snapback rally… Sep 28, 2026 • 3 min read Rising Treasury Yields Are Flashing a Warning for Stocks The 10-year Treasury yield just blew past 5%. Here’s why rising bond yields threaten stocks – and what to watch next… Sep 25, 2026 • 3 min read 1125 N Charles St, Baltimore, MD 21201 www.opportunistictrader.com To ensure our emails continue reaching your inbox, please add our email address to your address book. This editorial email containing advertisements was sent to reunisoft.cryptonews@blogger.com because you subscribed to this service. To stop receiving these emails, click here. The Opportunistic Trader welcomes your feedback and questions. But please note: The law prohibits us from giving personalized advice. To contact Customer Service, call toll free Domestic/International: 1-888-208-6550, Mon–Fri, 9am–5pm ET, or email us here. © 2026 Omnia Research, LLC. All rights reserved. Any reproduction, copying, or redistribution of our content, in whole or in part, is prohibited without written permission from Omnia Research, LLC. Privacy Policy | Terms of Use

The Nerve-Tech Name (Nasdaq: AMIX) That Just Crossed The Atlantic With Patent Protection

Picture an interventional suite.

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored The Nerve-Tech Name (Nasdaq: AMIX) That Just Crossed The Atlantic With Patent Protection *Click Here To Get Our Alerts Faster Via SMS* September 30th Greetings Readers, Picture an interventional suite. The arteries glow on the monitor in sharp detail. The nerves wrapped around them, the ones actually carrying the pain or driving the blood pressure, stay invisible. For decades, physicians have treated those nerves by anatomy and educated guesswork. A small team in The Woodlands, Texas, has been building a way to listen to them instead. Last Thursday, that work gained new protection in Europe. Autonomix Medical, Inc. (Nasdaq: AMIX) announced the grant of European Patent No. EP 4 233 700 B1, which covers systems that assess autonomic nerve activity through measurements taken in the eye. The company says the technology may support patient assessment, treatment guidance and procedural feedback across a range of neuromodulation uses. That grant didn't arrive alone. In July, Autonomix reported its portfolio had reached 112 issued or pending patent applications worldwide. A late-August U.S. patent covering feedback-guided neuromodulation then added protection for systems that pair real-time sensing with controlled therapy delivery. The human data is what first caught our eye. In the first phase of its first-in-human pancreatic cancer pain study, responding femoral-access patients saw mean pain scores fall from 7.89 to 3.22 at four to six weeks, a 59.2% improvement on the visual analog scale. A later post hoc analysis reported every responder was o-pioid fr-ee at the three-month follow-up. Regulatory groundwork is moving too. The company has completed its G-L-P preclinical study in porcine models across multiple anatomical targets, and says the data are expected to support its FDA submissions. Behind The Scenes: Inside The Readout When management walked through the G-L-P results in August, AMIX CEO Brad Hauser didn't frame them as a lab exercise. He said the final pathology and lab findings provide “important validation of our platform.” He also cast the milestone as part of the company's shift from preclinical development toward clinical-stage work. A few weeks later, the story moved to Copenhagen. Chief Medical Officer Dr. Robert Schwartz presented two accepted poster abstracts at CIRSE 2026: one on long-term pain mitigation in pancreatic cancer and one on mapping the nervous system with transvascular technology. That's the audience that would actually use a tool like this. The Pivot: From Cancer Pain To Blood Pressure And Beyond Pancreatic cancer pain is the entry point, not the ceiling. In July, Autonomix reported preclinical data from inside the renal arteries, where its catheter detected and localized renal nerve activity and confirmed changes after targeted ablation. Why does that matter? Today's renal denervation procedures for resistant hypertension are performed without direct physiological feedback, so physicians lean on anatomical landmarks. Autonomix wants to add a live nerve signal to that workflow. The boardroom now reflects that ambition. Sandra Cohen Kalter, former Vice President and Chief Regulatory Counsel at Medtronic, joined in September, bringing regulatory experience that includes Medtronic's Symplicity Spyral renal denervation system. Add a new U.S. patent for overactive bladder, a condition the company says affects an estimated 37Mn Americans, and the platform map keeps widening. The backdrop is a sizable, expanding category. MarketsandMarkets projects the global neuromodulation market could reach $10.68Bn by 2030, up from $6.81Bn in 2025. About Autonomix Medical, Inc. Autonomix is a medical device company. Its core is a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than currently available technologies, paired with targeted RF ablation. The company believes the platform could enable transvascular diagnosis and treatment of peripheral nerve disease virtually anywhere in the body. It has no product revenue yet. The regulatory plan, outlined when its G-L-P study began, runs through an IDE and U.S. clinical work supporting a De Novo FDA application. An expansion phase also covers additional visceral cancers beyond the pancreas. More Details And Sources: AMIX Website. AMIX Presentation. 6 Potential Catalysts Putting (Nasdaq: AMIX) On Our Watchlist #1. Fresh European Patent Extends Protection For Eye-Based Nerve Assessment. The newly granted EP 4 233 700 B1 gives (AMIX) European coverage for technology it says may support treatment guidance and procedural feedback. #2. Completed Study Feeds Directly Into Planned FDA Submissions. Management has said data from the finished G-L-P program are expected to support upcoming FDA filings for (AMIX). #3. Human Pain Data Showed Responders Stepping Away From Opioids. Post hoc PoC 1 data reported 100% of responders treated with the (AMIX) system were o-pioid fr-ee at three months. #4. Renal Denervation Adds A Potential Cardiovascular Growth Lane. Preclinical results showed the (AMIX) catheter could sense, localize, and confirm changes in renal nerve activity. #5. Low Float Profile Could Mean Heightened Volatility Ahead. Yahoo Finance lists a float of roughly 886.89K shares for (AMIX), so the potential for heightened volatility may be significant. #6. An Analyst Target Sits Well Above Tuesday’s Close. Maxim Group has pinned a $42 target on (AMIX). From Tuesday’s close, that target represents a potential 950+% upside. The Bottom Line Autonomix Medical, Inc. (Nasdaq: AMIX) has a clear thesis: nerves drive disease, and a catheter that can hear them could make nerve-targeted procedures far more precise. With G-L-P data complete, patents stacking up on two continents and a Medtronic regulatory veteran in the boardroom, AMIX is a name we think belongs on your radar. Pull up the filings, review the data and keep watching for its next FDA update. We’re kicking off coverage on Autonomix Medical, Inc. (Nasdaq: AMIX). Be on the lookout for updates coming soon. Talk again shortly. Sincerely, Kai Parker StockWireNews (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 09/29/2026 and ending on 09/30/2026 to publicly disseminate information about (AMIX:US) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC seventeen thousand five hundred USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid seventy five thousand USD ("Funds"). These Funds were part of the sixty thousand USD funds that TD Media LLC received from a third party named JRZ Capital LLC who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (AMIX:US). Please see important disclosure information here: https://stockwirenews.com/disclosure/amix-wkvsi/#details

SWN Media | 4808 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US Unsubscribe | Constant Contact Data Notice